Orkla Health   Report issue

For profit Phase 2
Founded: Oslo Norway (2004)
Status: No NME R&D (2004)

Organization Overview

First Clinical Trial
2008
NCT00631046
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2020

Timeline

NOW
  • Now

Alternative names

Axellus | Orkla | Orkla Care AB

Active Ingredients

Drugs in Phase 2 Trials (1)

rosehip (1 trial)

Drugs in Other Trials (6)

egg (1 trial)

fish oil (Omegavan) (1 trial)

menaquinone (vitamin k2) (1 trial)

salicylic acid (1 trial)

sunflower oil (1 trial)

whey protein (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Osteoarthritis (Phase 2)

Overview

  • Highest Phase: Phase 2
  • # of Trials: 6
  • # of Trial APIs: 7